MicroRNA as Upcoming Biomarkers for Psychiatric Conditions
Anoop Narahari*, Mariyah Hussain and Venkatesh Sreeram
University of Alabama, Department of Psychiatry and Behavioral sciences, Birmingham, Alabama, USA
- *Corresponding Author:
- Narahari A
University of Alabama
Department of Psychiatry and Behavioral sciences
Birmingham, Alabama, USA
E-mail: [email protected]
Received Date: August 31, 2015; Accepted Date: September 02, 2015; Published Date: November 15, 2015
Citation: Narahari A, Hussain M, Sreeram V (2015) MicroRNA as Upcoming Biomarkers for Psychiatric Conditions. Clin Depress 1:103. doi:10.4172/2572-0791.1000103
Copyright: © 2015 Narahari A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Neural derived exosomes can be used as a diagnostic marker to screen various psychiatric conditions. These intravenously injected exosomes carry the potential to cross the blood brain barrier and deliver miRNA specifically to neurons, microglia, and oligodendrocytes in the brain, resulting in a specific gene knockdown. MicroRNAs have been identified as markers in depression where miR-16 has been found to be a negative regulator of the serotonin transporter (SERT) through computer analysis. Futhermore, where miR 134 levels in bipolar disorder have been discovered to be inversely correlated with severity of manic symptoms; manipulating expression or activity of miR-219 can prove as a therapeutic tool for schizophrenia. Despite these studies, the exact nature and extent of dysregulation of microRNAs in psychiatric disorders is yet to be determined. To realize the therapeutic potential of MiRNAs in greater depth; efficient, tissue-specific and nonimmunogenic delivery of exosomes must be developed.